Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Charles M. Rudin

Charles M. Rudin

Department Affiliation: Primary:  Oncology
Degree: M.D., Ph.D., University of Chicago
Rank: Professor
Telephone Number: 410-502-0678
Fax Number: 410-502-0677
E-mail Address:  rudin@jhmi.edu
School of Medicine Address:  Cancer Research Building 2 Room 544, Baltimore, MD  21231

Novel anti-cancer drug development in lung cancer, integrating molecular and cellular models, preclinical tumor models, and early phase clinical trials.


Representative Publications:

Dr. Rudin's research is focused on the development and testing of novel treatments for lung cancer and other related diseases.  The Rudin laboratory studies new approaches to treating lung cancer in preclinical models, and Dr. Rudin oversees many early phase clinical trials, evaluating these approaches in patients.

  • Hann, C.L., Daniel, V.C., Hierman, J., Sugar, E., Cope, L., Lin, M., Watkins, D.N., Rudin, C.M.  Therapeutic efficacy of ABT-737, a selective inhibitor of Bcl-2, in small cell lung cancer.  Cancer Res. 68:2321-8, 2008.  Pub Med Reference


  • Riely, G.J., Rizvi, N.A., Kris, M.G., Milton, D.T., Solit, D.B., Rosen, N., Senturk, E., Azzoli, C.G., Brahmer, J.R., Seshan, V.E., Fogle, M., Ginsberg, M., Miller, V.A., Rudin, C.M.  Randomized phase 2 study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with stage IIIB or IV non-small cell lung cancer. J. Clin. Oncol. 27:264-70, 2009.   Pub Med Reference


  • Daniel, V.C., Marchionni, L., Hierman, J.S., Rhodes, J.T., Devereux, W.L., Rudin, C.M., Yung, R., Dorsch, M., Parmigiani, G., Peacock, C., Watkins, D.N.  A primary xenograft model of small cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69:3364-73, 2009.  Pub Med Reference


  • Rudin, C.M., Avila-Tang, E., Harris, C.C., Herman, J.G., Hirsch, F.R., Pao, W., Schwartz, A.G., Vahakangas, K.H., Samet, J.M.  Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin. Cancer Res.  15:5646-61, 2009.  Pub Med Reference


  • Von Hoff, D.D., LoRusso, P.M., Rudin, C.M., Reddy, J.C., Yauch, R.L., Tibes, R., Weiss, G.J., Borad, M.J., Hann, C.L., Brahmer, J.R., Mackey, H.M., Lum, B.L., Darbonne, W.C., Marsters, J.C., de Sauvage, F.J., Low, J.A.  Inhibition of the Hedgehog pathway in advanced basal cell carcinoma. New Engl. J. Med. 361:1164-1172, 2009.  Pub Med Reference


  • Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahan, C.A., Fu, L., Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., LoRusso, P.M., Von Hoff, D., de Sauvage, F.J., Low, J.A.  Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449.  New Engl. J. Med. 361:1173-1178, 2009.  Pub Med Reference


  • Yauch, R.L., Dijkgraaf, G.J.P., Alicke, B., Januario, T., Ahn, C.P., Holcomb, T., Pujara, K., Stinson, J., Callahan, A., Tang, T., Bazan, J.F., Kan, Z., Seshagiri, S., Hann, C.L., Gould, S.E., Low, J.A., Rudin, C.M., de Sauvage, F.J.  Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.  Science 326:572-4, 2009.  Pub Med Reference


  • Rudin, C.M., Poirier, J.T., Senzer, N.N., Stephenson, J., Loesch, D., Burroughs, K.D., Reddy, P.S., Hann, C.L., Hallenbeck, P.L.  Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.  Clin. Cancer Res. 17:888-95, 2011.  Pub Med Reference


  • Gandhi, L., Camidge, D.R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C.L., McKeegan, E.M., Litvinovich, E., Hemken, P.M., Dive, C., Enschede, S.H., Nolan, C., Chiu, Y.-L., Busman, T., Xiong, H., Krivoshik, A.P., Humerickhouse, R., Shapiro, G.I., Rudin, C.M.  A phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in subjects with small cell lung cancer and other solid tumors.  J. Clin. Oncol. 29:909-16.  Pub Med Reference


  • LoRusso, P.M., Rudin, C.M., Reddy, J.C., Tibes, R., Weiss, G.J., Borad, M.J., Hann, C.L., Brahmer, J.R., Chang, I., Darbonne, W.C., Graham, R.A., Zerivitz, K.L., Low, J.A., Von Hoff, D.D.  Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally advanced or metastatic solid tumors.  Clin. Cancer Res. 17:2502-11, 2011.  Pub Med Reference

Other graduate programs in which Dr. Rudin participates:

Cellular and Molecular Medicine
Cancer Epidemiology, Prevention, and Control

 
 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer